Quest Diagnostics (DGX) Tops Q2 EPS by 5c; offers guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.62, $0.05 better than the analyst estimate of $2.57. Revenue for the quarter came in at $2.76 billion versus the consensus estimate of $2.73 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.63-$9.83, versus the consensus of $9.70. Quest Diagnostics sees FY2025 revenue of $10.8-10.92 billion, versus the consensus of $10.795 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• CrowdStrike posts record ARR growth, raises full-year outlook